TX-TQ-DELTA
TQ Delta LLC, a technology development and licensing firm, secured another favorable judgment last week when a Delaware federal jury found that 2Wire Inc. infringed three of TQ Delta’s patents related to Digital Subscriber Line (“DSL”) technology. 2Wire is a subsidiary of ARRIS Solutions, which was recently acquired by CommScope Inc.
TQ Delta’s patents cover important memory sharing capabilities for DSL modems and central office equipment, among other inventions. TQ Delta notes that these inventions are widely employed not just in the United States, but around the world.
This ruling represents another victory for TQ Delta’s ongoing licensing business. Earlier this year, the High Court of Justice of England and Wales also found in favor of TQ Delta on another patent from its deep portfolio of DSL inventions. The UK Proceeding against ZyXEL Communications UK Ltd and its Danish parent company, ZyXEL Communications A/S (both subsidiaries of Unizyx Holding Corporation) found TQ Delta’s European Patent (UK) 1 453 268 valid and infringed, as well as essential to the standards for ADSL2 and VDSL2. The Court granted an immediate injunction and award of costs against the ZyXEL defendants. ZyXEL defendants have appealed some elements of the judgment and that appeal is pending. TQ Delta’s worldwide portfolio spans a broad range of standard essential patents (“SEPs”) and non-SEPs that are central to key broadband network technologies. In addition to validation by courts in the US and UK, TQ Delta has successfully licensed its technology to key market participants.
The most recent verdict was announced on May 23 following a nearly four-day trial in the United States District Court for the District of Delaware. After deliberation, the eight-member jury returned a favorable verdict on all eleven counts, finding that 2Wire infringed U.S. Patent nos. 7,836,381, 7,844,882 and 8,276,048, that those patents were not obvious over prior art, and that two certificates of correction were not invalid.
“We are pleased with the jury’s decision affirming the strength and importance of our portfolio of inventions, which are the culmination of years of investment in standards development and communications technologies,” said Abha Divine, Managing Director of TQ Delta.
TQ Delta has supported continued development of DSL markets by maintaining a longstanding business strategy designed to ensure advancements in the technology. “The TQ Delta portfolio and continued investment in the field contributes to the past, present, and future of high-speed DSL connections around the world. We have already licensed several companies to practice the important inventions under our DSL portfolio and will continue to seek to license others through business negotiations,” said Divine.
TQ Delta was represented by McAndrews, Held, and Malloy, Ltd., a firm specializing in intellectual property prosecution, counselling, and dispute resolution.
Lead trial attorney, Peter McAndrews, explained that “The Defendant’s strategy was to trivialize the important inventions at issue. We are pleased that the jury vindicated the inventors’ hard work and our client’s commitment to innovation.”
TQ Delta maintains a sizable patent portfolio for digital communication technology, including DSL.
About TQ Delta
TQ Delta is a technology development and licensing company aimed at providing needed solutions for the communications industry and beyond. The company’s technical investments span nearly two decades of contributions and innovation in the field of communications. TQ Delta’s technologies are used in leading products and services worldwide spanning broadband communications and media distribution. For more information, visit http://www.tqdelta.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005990/en/
Contact:
Scott Krady Magnitude, Inc. scott@magnitudegrowth.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
